New Anti-inflammatory Treatment Strategy in Alzheimer’s Disease
-
- Sugaya Kiminobu
- The Psychiatric Institute,West Side VA Medical Center,Department of Psychiatry,University of Illinois at Chicago,Chicago,IL 60612,USA
-
- Uz Tolga
- The Psychiatric Institute,West Side VA Medical Center,Department of Psychiatry,University of Illinois at Chicago,Chicago,IL 60612,USA
-
- Kumar Vinod
- The Psychiatric Institute,West Side VA Medical Center,Department of Psychiatry,University of Illinois at Chicago,Chicago,IL 60612,USA
-
- Manev Hari
- The Psychiatric Institute,West Side VA Medical Center,Department of Psychiatry,University of Illinois at Chicago,Chicago,IL 60612,USA
この論文をさがす
説明
Numerous reports have indicated that patients suffering from inflammatory diseases(e.g., arthritis)who take anti-inflammatory medication have a reduced risk of developing Alzheimer’s disease(AD).Thus, the first generation of anti-inflammatory cyclooxygenase(COX)inhibitors, such as aspirin and indomethacin, have been tested as potential therapeutics in AD.Because the inhibition of COX-1 is also known to cause tissue damage in the gastrointestinal system from the resultant reduced cytoprotection, selective COX-2 inhibitors are being investigated and tested clinically as potentially better therapeutics for AD patients.However, such drugs may also trigger unwanted effects;for example, the COX-2 inhibitors, which reduce the production of one type of eicosanoids, the prostaglandins, may increase the production of other eicosanoids;i.e., the leukotriene B4(LTB4), which is one of the most potent endogenous chemotactic/inflammatory factors.LTB4 production is initiated by the enzyme 5-lipoxygenase(5-LOX).The expression of the 5-LOX gene is upregulated during neurodegeneration and with aging.In spite of the fact that 5-LOX and leukotrienes are major players in the inflammation cascade, their role in AD pathobiology/therapy has not been extensively investigated.We propose that the 5-LOX inflammatory cascade may take part in the process of aging-associated neurodegenerative diseases, and we point to the role of 5-LOX in neurodegeneration and discuss its relevance for anti-inflammatory therapy of AD.
収録刊行物
-
- Jpn.J.Pharmacol.
-
Jpn.J.Pharmacol. 82 (2), 85-94, 2000
公益社団法人 日本薬理学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204286877568
-
- NII論文ID
- 10008182822
-
- NII書誌ID
- AA00691188
-
- COI
- 1:CAS:528:DC%2BD3cXhsVOgtbw%3D
-
- ISSN
- 13473506
- 00215198
-
- NDL書誌ID
- 5283857
-
- PubMed
- 10877525
-
- Web Site
- http://id.ndl.go.jp/bib/5283857
- https://ndlsearch.ndl.go.jp/books/R000000004-I5283857
- https://api.elsevier.com/content/article/PII:S0021519819307012?httpAccept=text/xml
- https://api.elsevier.com/content/article/PII:S0021519819307012?httpAccept=text/plain
- https://www.jstage.jst.go.jp/article/jjp/82/2/82_2_85/_pdf
- https://search.jamas.or.jp/link/ui/2000143178
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可